Sleeping Beauty, Mice, & Dogs: \u3cem\u3eCell Death in Narcolepsy\u3c/em\u3e by Duncan, D\u27Anne
Eukaryon
Volume 1 Article 10
1-2005
Sleeping Beauty, Mice, & Dogs: Cell Death in
Narcolepsy
D'Anne Duncan
Lake Forest College
Follow this and additional works at: http://publications.lakeforest.edu/eukaryon
Part of the Biology Commons, and the Cell Biology Commons
Disclaimer:
Eukaryon is published by students at Lake Forest College, who are solely responsible for its content.
The views expressed in Eukaryon do not necessarily reflect those of the College. Articles published
within Eukaryon should not be cited in bibliographies. Material contained herein should be treated
as personal communication and should be cited as such only with the consent of the author.
This Review Article is brought to you for free and open access by Lake Forest College Publications. It has been accepted for inclusion in Eukaryon by an
authorized administrator of Lake Forest College Publications. For more information, please contact levinson@lakeforest.edu.
Eukaryon, Vol. 1, 33-38, January 2005, Lake Forest College                                                                             Review Article
Sleeping Beauty, Mice, & Dogs:  Cell Death in
Narcolepsy
D’Anne Duncan*
Department of Biology
Lake Forest College
Lake Forest, Illinois 60045
[Role Playing Jerome M. Siegel
Department of Psychiatry,
University of California at Los Angeles
Los Angeles, California]
Summary
Sleep is important and required for the survival and
normal homeostasis of vertebrates.  Disturbances
in the sleep-wake cycle can lead to many sleep
disorders, one of which is narcolepsy.  Narcolepsy
is a disabling sleep disorder characterized by
excessive daytime sleep, cataplexy (sudden loss of
muscle tone in response to strong emotion or
laughter), hallucinations, and sleep paralysis.  To
date, the pathological and biological basis of
narcolepsy is poorly understood.  My lab first
discovered, in canines and humans, dysfunctional
neurons that affect the sleep-wake cycle in
narcolepsy, as well as neurodegeneration of
brainstem and hypothalamic neurons. Other labs
have identified mutations in hypocretin (orexin)
receptor genes in canine narcoleptics.  An orexin
knockout mice model mimics the narcoleptic
phenotype seen in humans and dogs.  More
recently, a hypocretin gene mutation has been
identified in at least one human narcoleptic.  Given
that orexin is critical for the regulation of feeding
behavior, opens the door to investigate energy
homeostasis in narcolepsy, as well as in finding a
treatment.
Sleep
Sleep is important and required for the survival and
normal homeostasis of vertebrates1.  Sleep occurs in all
mammals; if deprived of it the outcome can be fatal1.
The sequence of brain states that define sleep are
governed by a series of controlled brain states, by
brainstem nuclei that project throughout the brain and
spinal cord1.
Many physiological changes take place
during non-REM and REM sleep.  Non-REM sleep is
characterized by decreases in muscle tone, heart rate,
breathing, blood pressure, and metabolic rate.  In
contrast, during REM sleep, there is an increase in
blood pressure, heart rate, and metabolism, as much as
seen in the awake state1.  The most prominent area of
the brain that governs sleep and wakefulness is the
hypothalamus, which is the regulator of temperature,
heart rate, blood pressure, food and water intake, other
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brainstem nuclei, and, most importantly, the sleep-wake
cycle.
Humans descend into REM after an hour or
so of sleeping.   In the drowsy period, also known as
Stage I sleep, the frequency spectrum of the
electroencephalogram (EEG) is shifted to lower
numbers, and the amplitude of cortical waves slightly
increases.  Stage II is characterized by the further
decrease in the frequency of the EEG waves, and an
increase in amplitude as well as the increase of high-
frequency spike clusters called sleep spindles.  Sleep
spindles are periodic bursts of activity at about 10-12
Hz.  Stage III represents deep sleep, in which the
number of sleep spindles decreases.  The deepest level
of sleep, known as stage IV, consists of low activity of
EEG, and high-amplitude fluctuations known as delta
waves.  All of these stages are called non-rapid eye
movements (non-REM) sleep, and the feature is slow-
wave sleep; it is most difficult to awaken people from
this stage of sleep.   Following non-REM sleep, rapid
eye movement (REM) sleep, in which EEG recordings
are similar to the awake state. The brainstem nuclei
responsible for wakefulness are the cholingeric nuclei
of the pons-midbrain junction, locus coeruleus, and
raphe nuclei; in this state these brainstem neurons are
active.  A malfunction in one of these brainstem nuclei
can lead to one of the many sleep disorders: insomnia,
sleep apnea, “restless legs syndrome” and the most
well understood biologically, narcolepsy 1.
Narcolepsy
Narcolepsy is a disabling sleep disorder characterized
by excessive sleepiness during normal waking hours2.
In other words, an individual with narcolepsy has
frequent “REM sleep attacks” during the day without
going through non-REM sleep1.  It affects approximately
1 in 2,000 individuals (about 125,000 individuals in the
U.S.), with both sexes being equally affected, and it
develops in the second or third decade of life with
symptoms progressing over a period of 1 or more years
and then stabilizing 3.
Signs and Symptoms
Narcolepsy is characterized by excessive daytime
sleepiness (EDS), which is the first sign and important
symptom; cataplexy, which is the sudden loss of
muscle tone in response to strong emotions such as
laughter or anger; hyponagogic hallucinations, dream-
like experiences occurring at the onset of sleep, and
sleep paralysis, the inability to move while falling asleep
or upon waking4. Narcolepsy is defined by the presence
of sleepiness and cataplexy or by the
polysomnographic documentation of REM sleep
abnormalities.  The most commonly accepted
diagnostic test is the multiple sleep latency test (MSLT),
in which nocturnal sleep somnography is performed
followed the next day by 4 to 5 daytime naps in which
sleep latency is measured4.
Treatments
The most common treatment of narcolepsy, EDS, is
treated with amphetamine-like stimulants or modafinil,
drugs that stimulate dopamine release as well as inhibit
dopamine reuptake (necessary for narcolepsy). Cataplexy is treated with tricyclic antidepressants or
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Figure 1.  A Working Model for Narcolepsy
Normally, hypothalamic neurons project onto three specific brainstem nuclei involved in arousal regulation; locus coeruleus (LC), raphe
nucleus (RN), and cholingeric (Ach) neurons; all of which when active induces wakefulness in organisms.  In narcolepsy, the death of
hypothalamic neurons may cause these brainstem nuclei to become inactive, and induce REM sleep, decreasing the onset of wakefulness.
higher doses of serotonin reuptake inhibitors4.  Even
though there are treatments to reduce the onset of the
symptoms of narcolepsy, there is no specific cure.
Pathology
Hypocretin (orexin) neurons have been found to be
associated with the pathology of narcolepsy.  These
neurons project to brainstem nuclei that are associated
with motor inhibition, and more importantly to locus
coerulus (LC), raphe, and acetylcholine nuclei.
Hypocretin neurons also project to forebrain regions,
including the hypothalamus and amygdala.  It has been
illustrated that loss of the hypocretin system could in
fact cause cataplexy through the inhibition of the
brainstem’s motor excitatory system or exciting the
brainstem’s motor inhibitory system (See Figure1).  The
loss of hypocretin facilitates sleepiness by decreasing
the body’s arousal system3.
Gaps in Knowledge
Even though there is an understanding of the pathology
of narcolepsy, scientists are still unaware of the
mechanism that leads to the loss of the hypocretin
system.  Are these neurons dying?  Also, the genetics
and cause of human narcolepsy are still unkown.
Scientists chose to examine the cellular mechanism
associated with the onset of narcolepsy.
Animals of Choice
Narcolepsy was established in canines, more
specifically reported in Dachshunds and Poodles, to be
transmitted through autosomal recessive inheritence3.
More recently, narcolepsy has been induced in other
breeds.  These breeds of dogs, Doberman Pinschers
and Labrador Retrievers, were used to establish a
narcoleptic dog-breeding colony at Standard in 19764.
These narcoleptic dogs display the same symptoms as
human narcoleptics; both display emotionally triggered
cataplexy, fragmented sleep, and short sleep latency4.
Cataplexy can be easily induced in these animals by
presenting them with food or by play4.  There have also
been mice models that display similar narcoleptic
phenotype.
First Suggestions on Narcolepsy
In narcoleptic dogs, as well as humans, cataplexy is
one of the most prominent signs of narcolepsy; it was
suggested that cataplectic neurons are not being
triggered for a successful sleep/wake cycle.  In 1991,
the first investigation of cataplectic neurons took place
in my lab.  We investigated noncholigernic cells in the
medial medulla of the narcoleptic dogs.   We found that
these cataplexy-off neurons had a decreased firing rate
during cataplexy, while brain activity was active.  These
neurons were in fact active during REM sleep as well.
Also discovered was that neurons did not fire at all
during cataplexy, while during quiet and active waking
and REM sleep specific neurons had a higher
discharging rate than during cataplexy5.
This study suggests that there was an
abnormal discharge patterns of certain neurons during
the onset of cataplexy.  The next approach we needed
to take was to determine the specific neurons that are
discharging during cataplectic attacks in canine
narcoleptics.
Locus Coerulus Neurons in Canine Narcoleptics
Following the study conducted in 1991, eight years
later, the identification of locus coerulus neurons firing
during cataplexy was completed.   As mentioned
previously, locus coerulus (LC) nuclei are involved with
the onset of wakefulness in the sleep/wake cycle.  LC
neurons fire during both quiet and active waking; they
discharge during arousal in response to stress as well
as sensory stimulation6.
In this study, LC neurons were recorded
during normal sleep states and during cataplexy in
narcoleptic dogs to evaluate the activity of LC neurons
in narcolepsy.  Our results suggested that LC neurons
were discharging at a lower rate during cataplexy than
that seen in REM sleep.  Due to the loss of LC neurons,
we came to the conclusion that these neurons played a
role in the loss of muscle tone (characterized by
cataplexy) and REM sleep: two major symptoms of
canine and human narcolepsy.  The identification of
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these neurons allowed us to determine if they were
undergoing cell death due to the lower  discharge rate6.
Are Cells Dying Causing Narcolepsy?
In 1999, my lab conducted another experiment in which
we tested the hypothesis of neurodegeneration causing
narcoleptic symptoms in canines. At that time, my lab
established that narcolepsy is not a progressive
disorder, meaning that once symptoms are established,
they do not become worse7.  We found elevated levels
of axonal degeneration in the basal forebrain,
amygdala, peduncular nucleus, and medial septal
region, all of which have implications with the
hypothalamus7.  These disinhibited neurons are
activated during sudden, strong emotion; which in turn
inactivates the locus coerulus, resulting in cataplexy7.
We also discovered that the axonal degeneration
coincided with the onset of narcolepsy, suggesting that
the discharge rate of specific neurons in the brain near
the hypothalamus may be one of the mechanisms that
causes narcolepsy.
To determine whether the degeneration of
neurons leads to symptom onset, we used amino-cupric
silver staining that specifically stains for axonal
degeneration in the brain7. Surprisingly, there was no
axonal degeneration seen in human narcoleptics, only
in canine narcoleptics at that time.
New Leads on Narcolepsy
Till date, only the identification of LC, as well as the
neurons undergoing neurodegeneration was unknown
until the identification of other genes involved with
sleep/wake and feeding cycle by two of my colleagues:
Emmanuel Mignot and Masashi Yanagisawa (1998).
The Identification of Hypocretin (Orexin)
Hypocretins (orexin) are two carboxy-terminated
neuropeptides, which are produced from a common
precursor known as prepro-orexin8.  These
neuropeptides have been found to be expressed only in
the hypothalamus, which is the center for the
sleep/wake cycle, as well as feeding and homeostasis8.
The hypocretins have been detected in secretory
vesicles at synapses of fibers that project to areas
within the hypothalamus that have been identified as
having implications with feeding behaviors and
hormone secretion 8.  Is hypocretin involved with
narcolepsy, since found in the hypothalamus?
Identification of Orexin & Orexin-Receptors
In 1998, Yanagisawa and colleagues identified orexin
and orexin receptors, as well as their role in the
regulation of feeding habits in mice.  They identified two
neuropeptides, both of which derived from prepro-
orexin, which activate two G-protein coupled receptors
(GPCR’s) located in the hypothalamus9. In order to
identify orexin as well as orexin receptors, they used a
systematic approach for peptide ligands of multiple
orphan GPCR’s9.
Through in situ hybridization, the visualization
of neurons containing prepro-orexin mRNA was
characterized in hypothalamic areas of the brain9.
Results suggested that the prepro-orexin neurons were
found predominantly in these areas, suggesting that the
protein would be involved in the sleep/wake cycle, as
well as feeding and homeostasis9.
Yanagisawa and colleagues also established
in rats that as the amount of food stimulus and
consumption increased so did the amount of orxein-A
and orexin-B in the brain9.  In addition, they also
identified that prepro-orexin mRNA was upregulated in
fasted rats as compared with fed rats.  They found
there was more orexin mRNA found in rats that were
fasted9.  The identification of orexin-A and orexin-B as
well as their receptors was a significant finding because
of its implications with feeding behaviors, which is
associated with the hypothalamus.  The next question
to ask is, are these peptides involved with narcolepsy?
Mutation in Hypocretin Leads to Narcolepsy
In 1999, a breakthrough took place with Emmanuel
Mignot and colleagues, who discovered the genetics of
narcolepsy.  The lab team established an autosomal
recessive mutation in the hypocretin (orexin) receptor 2
gene (Hcrtr2) in canine narcoleptics10.  Mignot et al.,
through the use of positional cloning, identified three
mutations in Hcrtr2 in Doberman, Labrador, and
Dachshund canines10.  First, they identified a 226 bp
short interspersed nucleotide element (SINE) that was
inserted upstream of the 3’ site of the fourth exon10.
This led to the conclusion that the mutation leading to
the loss of exon 4 will possibly produce truncated
hypocretin protein11.  The SINE insertion was found in
17 narcoleptic Dobermans, however was absent in the
Labrador and Dachshund narcoleptics11.  Second,
analysis of cDNA from narcoleptic Labradors identified
a 123 bp deletion of exon 6.  Third, also shown in
narcoleptic Labradors, a G to A point mutation was
identified in the 5’ splice site11.
It was hypothesized that the disrupted
splicing of Hcrtr2 mRNAs leads to truncated proteins
that may lead to the symptoms associated with
narcolepsy.  Also, mutations in Hcrtr2 receptor may
lead to hyperexcitiability of REM sleep generator
neurons, or the inhibition of REM sleep neurons,
leading to narcolepsy11. A gap in knowledge at that time
was, is there a mutation in Hcrtr2 leading to the
truncation of proteins found in human narcoleptics, not
only canine narcoleptics?
Truncation of Proteins
In 2001, Mignot et al., illustrated the function of mutated
hypocretin in canine narcoleptics.  In a human cell line,
they identified a point mutation (E54K) and previously
described exon-skipping mutations, leading to the
truncation of Hcrtr2 protein12.  This truncated protein
indicated the absence of proper membrane localization,
as well as undetectable binding and signal transduction
for mutants12.  The absence leads to canine narcolepsy,
and addresses the gap in knowledge of the role of
hypocretin truncated protein with narcolepsy.
Knock-Knock!  It’s Orexin...Orexin Who?
In the same month as the identification of the mutation
of Hcrtr2 in canine narcoleptics, Yanagisawa et al.,
created an orexin knock-out mouse model to further
understand the genetics behind sleep regulation and
narcolepsy.  They reported that through the use of
behavioral and EEG recordings, orexin knock-out mice
exhibited a phenotype quite similar to human and
canine narcoleptics13.  Yanagisawa et al., discovered
that orexin knock-out mice had a lack of orexin present
in the hypothalamus through the use of
immunohistochemistry13.
Orexin knock-out mice had very distinct
motor behaviors as compared to the normal mice.
Through the use of infrared videophotography, they
discovered that orexin knock-out mice had multiple
behavioral arrests during the dark phase (at night)13.
All nine knock-out mice encountered several narcoleptic
attacks during the first four hours of the onset of
darkness, when mice are normally most active13.   They
also reported, through EEG recordings, significantly
more frequent patterns of REM sleep as compared to
wild-type mice.  Also, compared to wild-type mice,
orexin knock-out mice had a more immediate decrease
in muscle tone at the onset of a narcoleptic attack,
through the observations of EEG recordings13.
Yanagisawa et al., also tested the hypothesis
that orexin neurons innnervate critical sleep-
wakefulness brainstem nuclei13.  Through the use of
double immunostaining techniques, they found orexin
cell bodies, as well as dendrites in histaminergic
neurons; orexin immunoreactive fibers on nonadregenic
neurons of the locus coerulus (center of wakefulness);
orexin fibers also innervated serotonergic neurons in
the raphe nucleus13.  All of these brainstem nuclei have
been previously hypothesized if turned off may
contribute to the pathology associated with narcolepsy.
To conclude this study, orexin and orexin receptors are
essential pathway that lead to the regulation of the
sleep/wake cycle; malfunction in this system can
possibly lead to narcolepsy in humans.
Forget Dogs & Mice...Now Humans and Narcolepsy
In 2000, Mignot et al. finally established a connection in
human cases of narcolepsy.  They measured the
amount of immunoreactive hypocretin in the
cerebrospinal fluid of nine narcoleptic patients and
eight-control patients14.  They discovered a hypocretin
deficiency in narcoleptic patients.  Of the nine
narcoleptics who experienced episodes of cataplexy,
seven had a significantly decreased concentration of
hypocretin found in the brain14.  This decreased
transmission of hypocretin suggested that low
concentrations of hypocretin leads to the development
of narcolepsy14.  With this study, my lab was able to
further implicate the decreased transmission of
hypocretin may lead to narcolepsy in humans.
Reduced Number of Hypocretins (Orexin) in Human
Narcoleptics
In 2000, my lab team established that there is a
significantly decreased amount of hypocretin neurons in
human narcoleptics as compared with normal patients.
We found that there was an 85-95 % reduction of
hypocretin neurons found in human narcoleptics,
suggesting that the degeneration of these neurons is
possibly responsible for the symptoms of narcolepsy15.
We immunostained the hypothalamus of 16 human
brains for hypocretin (Hcrt), including four narcoleptics.
There was a minimal amount of Hcrt staining present in
the narcoleptic brains15.  In fact, there was a dramatic
loss of Hcrt cells in the hypothalamus.
To assess the idea that Hcrt neurons were
specifically undergoing degeneration, we stained for
melanin-concentrating hormone neurons (MCH)15.  We
found that MCH neurons were not dying, only Hcrt
neurons. We also discovered that there was an
upregulation of gliosis in the hypothalamus of
narcoleptic patients, as compared with controls15.  The
presence of gliosis suggests that neurodegernation was
taking place within the brain; more specifically, the
reduced number of Hcrt neurons in narcoleptics is
caused by neurodegeneration15, as seen previously in
canine narcoleptics in a study conducted by my lab in
1999.
Mutations and Humans
Also in 2000, a mutation in a case of early onset of
human narcolepsy was identified.  Through the analysis
of histopathology, seventy-four narcoleptic patients
were screened for mutations of Hcrt gene, Hcrt1 gene,
and Hcrtr216.  Of the seventy-four patients, there was
one Hcrt gene mutation (early onset of narcolepsy) that
led to impaired peptide trafficking and processing16.
They discovered that the wild-type Hcrt protein went
through the Golgi network into secretory vesicles
through the use of green fluorescent protein (GFP) or
V5 epitope tags16.  The mutant Hcrt protein remained in
the membrane system and thus was not able to pass
through the Golgi. The dominant mutation observed
was a point mutation of a leucine to an arginine in one
case of human narcolepsy16. A mutation in the Hcrt
leads to impaired trafficking, which will then cause the
onset of narcolepsy16.  This mutation found in one
human patients, opened the door to assess narcolepsy
in humans further through future studies.
Narcolepsy, Feeding Behavior, & Orexins
In 2001, Yanagisawa and colleagues made a huge leap
to associate orexin neurons and how they regulate
narcolepsy, hypophagia, and obesity in mice.  They
generated a transgenic mouse model in which they
ablated the orexin expression17.  They attached an
orexin promoter to a Machado-Joseph Disease (MJD)
gene (ataxin-3), in which they observed that the orexin
neurons were dying due, to the expression of the
mutant MJD protein.   These mice showed a similar
phenotype to human narcoleptic patients, including
behavioral arrests, premature entry in REM sleep, and
late-onset obesity17.
To assess the ablation of orexin/ataxin-3
transgenic mice, immunohistochemistry was employed.
They observed in the wild-type mice more orexin
neurons as the mice increased in age, as compared
with the transgenic mice, which had a significant
number of orexin neurons at four weeks17. As time
passed, however, the number of orexin significantly
decreased, implying neurodegeneration17.
According to EEG/EMG recordings, they
observed that even though the brain was active in Tg
mice, there was a loss of muscle tone during the onset
of REM sleep17.  In relation to orexin and feeding
behavior, this lab team found that orexin/ataxin-3 mice
showed late-onset obesity17.  That obesity occurred
even though there was a 30% reduction in food intake,
suggesting that orexin-neurons play a role in the
regulation of feeding behavior and energy
homeostasis17.  One can speculate that the energy
expenditure of these mice decreased, resulting in the
differences in motor activity caused by the pathology
associated with narcolepsy. Reduced feeding and
obesity may reflect an underlying reduction in energy
expenditure due to decreased motor activity (storing
more fat), lower basal metabolic rate, or the
combination of both17. This study indicates that
metabolic abnormalities in food intake and/or energy
expenditure may exist in human narcolepsy17. Another
major conclusion that brings symptoms associated with
narcolepsy is role of orexin neurons in the
hypothalamus.
Another facet associated with orexins is
leptin.  Leptin is a hormone shown to modulate food
intake and energy expenditure, as well as fat and
glucose metabolism18.  Basically, leptin tells the body
that ‘it is full’ after eating18.  Leptin appears to function
largely within the long-term system and influences the
quantity of food consumed relative to the amount of
energy expended18.  Leptin has been shown to
stimulate the activity of orexins in the lateral
hypothalamus19, which is important for the
understanding of the relationship between orexins,
feeding, and narcolepsy.  Orexin neurons have been
associated not only with the regulation of the sleep-
wake cycle, but more recently suggest a role in the
regulation of energy homeostasis17, which may lead
into the insight of narcolepsy and possible treatments
(See Figure 2).  Possibly cell death or
neurodegeneration of orexin neurons may lead to
obesity, which may have implications with the onset of
narcolepsy.
Figure 2.  A New Working Model for Narcolepsy
When the body undergoes weight loss, an increase of leptin, a
protein involved with the regulation of feeding, increases the
amount of orexin (hypocretin) produced in the hypothalamus.
The body in turn recognizes the increase in orexin as
starvation, and increases the food intake and the decrease in
energy expenditure.  On the other hand, with weight gain, there
is an increase in leptin, which decreases the amount of orexin
(due to cell death) produced in the hypothalamus.  The down-
regulation of orexin decreases food intake and increases
energy expenditure which leads to obesity, which may lead to
narcolepsy.
Present Research with Orexins and Muscle Tone
My lab investigated the role of orexins and muscle tone,
since loss of muscle tone is one of the symptoms of
narcolepsy.  We injected both orexin-A and orexin-B
into the locus coerulus in the hypothalamus20.  We
discovered that the injections of orexin-A and orexin-B
correlated with muscle-tone facilitation20.  Orexins are
involved with muscle-tone facilitation; without these
specific neurons there would be a loss of muscle tone,
which may lead to symptoms of narcolepsy.  The next
question addressed was does is hypocretin regulated in
the sleep/wake cycle in other models?
Present Day Research of Narcolepsy & Sleep/Wake
Cycle
In 2002, my lab investigated the amount of Hcrt during
the different sleep stages.  Instead of using the canine
model, looked into cats for the answer with Hcrt.  We
found in the hypothalamus a significant difference in
Hcrt concentrations during the active-wake, quiet-wake,
slow-wave-sleep (similar to non-REM sleep), and REM
sleep stages21.  This in turn suggested that hypocretin
is involved with the sleep/wake cycle, which contributes
to the symptoms associated with narcolepsy21.
New Findings Associated With Cataplexy &
Narcolepsy in 2002
Since the amygdala is associated with the emotion
process in the brain, my lab hypothesized that specific
neurons are changing their properties, which may be
linked to cataplexy. We investigated this hypothesis in
the canine model and discovered that two populations
of cells showed a significant change in activity with
cataplexy22.  More specifically, a set of sleep-inducing
neurons increased their discharge rate prior to
cataplectic attack; on the other hand, a set of wake
inducing neurons decreased their discharge rate prior
to cataplectic attacks as seen in narcolepsy22.  This
study suggests that the abnormality of these neurons
leads to cataplexy, which is seen in both human and
canine narcoleptics.
Contradictions of Narcolepsy
There are a few contradictions in the field of
narcolepsy.  One major question is are these specific
neurons that causes narcolepsy?  One may find that
neurons are dying, while another finds that these
neurons have an abnormal firing rate.
Challenges Ahead in Narcolepsy
Others have illustrated that orexin plays a role in the
regulation of feeding, and more recently how
narcolepsy and feeding behavior is connected.  The
next approach will be to further assess the role of
orexins (possibly cell death) in narcoleptic humans to
see if that hypothesis holds true.  Understanding
obesity and orexins in humans will not only allow for a
possible cure of an epidemic in the U.S., as well as
possible treatments for narcolepsy.  Also through the
understanding of energy expenditure, we can learn
more about obesity, more importantly narcolepsy.
Conclusion
Narcolepsy is a non-progressive neurodegenerative
disorder that affects 1 in 2,000 Americans each year.
Research conducted in my lab has enabled the
identification of the death of specific neurons found in
the hypothalamus leads to the pathology of narcolepsy
seen in both canine and human narcoleptics.  Other
labs have established mutations in hypocretin (orexin)
genes associated with narcolepsy.  With the
collaboration of my lab, as well as other labs, a
treatment for narcolepsy can be found in the near
future.
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